-
Article
Open AccessBasal Insulinotherapy in Patients Living with Diabetes in France: The EF-BI Study
Second-generation basal insulins like glargine 300 U/mL (Gla-300) have a longer duration of action and less daily fluctuation and interday variability than first-generation ones, such as glargine 100 U/mL (Gla...
-
Article
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs
An ambitious reform of the early access (EA) process was set up in July 2021 in France, aiming to simplify procedures and accelerate access to innovative drugs.
-
Article
Open AccessCorrection: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
-
Article
Open AccessESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
Prophylactic central neck dissection in clinically low-risk cT1bT2N0 papillary thyroid carcinoma is controversial, due to a large number of conflicting retrospective studies, some showing an advantage in terms...
-
Article
Post-operative radioactive iodine administration in patients with low-risk thyroid cancer
Radioactive iodine (RAI) treatment is used in patients with thyroid cancer to treat disease and to eradicate normal thyroid remnants. Routine post-operative administration of RAI is no longer indicated in pati...
-
Article
Open AccessRADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer
This is the first prospective trial evaluating the efficacy of alpha emitter Radium-223 in patients with bone metastases from radioactive iodine (RAI) refractory (RAIR) differentiated thyroid cancer.
-
Article
Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer
Vandetanib is indicated for adults with advanced medullary thyroid cancer (MTC).
-
Article
Open AccessProjecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates
Within (European) healthcare systems, the predominant goal for pharmaceutical expenditure is cost containment. This is due to a general belief among healthcare policy makers that pharmaceutical expenditure—dri...
-
Article
Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy
Background The role of olanzapine in the treatment of chemotherapy-induced nausea and vomiting (CINV) in addition to the antiemetic therapeutic combination with aprepitant, setrons, and corticosteroids has not be...
-
Article
Follow-up of differentiated thyroid cancer – what should (and what should not) be done
The treatment paradigm for thyroid cancer has shifted from a one-size-fits-all approach to more personalized protocols that range from active surveillance to total thyroidectomy followed by radioiodine remnant...
-
Article
Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients
Interferon-alpha (IFN-alpha) is recommended in neuroendocrine tumors (NET). Malignant pheochromocytoma and paragangliomas (MPPGLs) constitute a rare subgroup of NET with few treatment options. IFN-alpha effica...
-
Article
The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer
In patients with metastatic differentiated thyroid carcinoma (DTC), fluorodeoxyglucose (FDG) uptake as well as age, tumor size and radioactive iodine (RAI) uptake are prognostic factors for survival. High FDG ...
-
Article
Anatomic Variability of the Upper Mediastinal Lymph Node Level VII
Lymph node level VII, between the sternal notch and the innominate artery, is a frequent site of lymph node metastases in thyroid cancer. The objective of this study was to determine the cranial–caudal dimensi...
-
Article
Open AccessFrench Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends
France is one of the European countries that spend the most on oncology drugs. To keep pharmaceutical expenditure under control, Health Authorities highly scrutinize market access of costly medicines.
-
Article
Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review
Prophylactic neck dissection (PND) for papillary thyroid carcinoma (PTC) is controversial. Our aim was to assess current levels of evidence (LE) according to the Oxford Centre for Evidence-based Medicine ( ...
-
Article
The Cost of Thromboembolic Events in Hospitalized Patients with Breast or Prostate Cancer in France
The aim of the present study was to determine the number of admissions and the cost of hospital management of venous thromboembolism (VTE) events occurring in patients with breast cancer (BC) or prostate cance...
-
Article
Open AccessCost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
The IFCT-GFPC 0502 phase III study reported prolongation of progression-free survival with gemcitabine or erlotinib maintenance vs. observation after cisplatin–gemcitabine induction chemotherapy for advanced non-...
-
Article
Prophylactic Level II Neck Dissection Guided by Frozen Section for Clinically Node-Negative Papillary Thyroid Carcinoma: Is It Useful?
Prophylactic lateral neck dissection (PLND) is generally not performed for papillary thyroid carcinoma (PTC). When performed, occult metastases are found in up to 50 % of patients, although the incidence of oc...
-
Article
Influence of Prophylactic Neck Dissection on Rate of Retreatment for Papillary Thyroid Carcinoma
Prophylactic neck dissection (PND) for papillary thyroid cancer is controversial. The objective of this study was to analyze the influence of PND on the rate of retreatment.
-
Article
Treatment and follow-up of low-risk patients with thyroid cancer
This Perspectives re-evaluates the role of radioiodine treatment following surgery in low-risk patients with undetectable serum thyroglobulin levels after TSH stimulation and without evidence of disease. Moreo...
